MEDI-528, now recognized as enokizumumab, represents a groundbreaking therapeutic targeting the insulin-like growth factor 1 receptor , a vital protein linked in various skin conditions . Early trial results suggest considerable efficacy for the control of significant atopic dermatitis , particularly in those who have responded poorly to convention